Gemphire Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.42 |
Market Cap |
$10.84 M |
Shares Outstanding |
14.27 M |
Public Float |
10.22 M |
Address |
17199 North Laurel Park Drive Livonia Michigan 48152 United States |
Employees | - |
Website | http://www.gemphire.com |
Updated | 07/08/2019 |
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand. |